Conditions: Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 29
Healthy volunteers: no

Brief summary:
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.

Detailed description:

Arms:
arm 1: INCB018424 Ruxolitinib 0.5% vs vehicle applied once daily for 28 days arm 2: INCB018424 Ruxolitinib 1.0% vs vehicle applied once daily for 28 days arm 3: INCB018424 Ruxolitinib 1.5% vs vehicle applied twice for 28 days arm 4: INCB018424 up to 1.5% versus Dovonex® calcipotriene 0.005% cream applied BID for 28 days arm 5: INCB018424 up to 1.5% versus Diprolene ® AF betamethasone dipropionate 0.05% cream applied twice a day for 28 days

Interventions: intervention 1: Ruxolitinib phosphate cream intervention 2: Dovonex® calcipotriene 0.005% intervention 3: Diprolene® AF betamethasone dipropionate 0.05% cream. intervention 4: Placebo cream intervention 5: Ruxolitinib phosphate cream intervention 6: Ruxolitinib phosphate cream
Intervention descriptions: intervention 1: Ruxolitinib phosphate cream 0.5% intervention 2: Cream applied once or twice daily for up to 56 days. intervention 3: Cream applied once or twice daily for up to 56 days intervention 4: Cream applied once or twice daily for 56 days intervention 5: Ruxolitinib phosphate cream 1.0% intervention 6: Ruxolitinib phosphate cream 1.5%

Protocol document: